company background image
A049180 logo

CellumedLtd KOSDAQ:A049180 Stock Report

Last Price

₩1.79k

Market Cap

₩76.7b

7D

6.4%

1Y

-67.7%

Updated

27 Mar, 2024

Data

Company Financials

A049180 Stock Overview

Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea.

A049180 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Cellumed Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CellumedLtd
Historical stock prices
Current Share Price₩1,792.00
52 Week High₩7,300.00
52 Week Low₩1,600.00
Beta0.58
1 Month Change-6.72%
3 Month Change-16.65%
1 Year Change-67.65%
3 Year Change-72.85%
5 Year Change-80.77%
Change since IPO-83.01%

Recent News & Updates

Recent updates

Shareholder Returns

A049180KR Medical EquipmentKR Market
7D6.4%8.9%3.8%
1Y-67.7%45.3%13.0%

Return vs Industry: A049180 underperformed the KR Medical Equipment industry which returned 45.3% over the past year.

Return vs Market: A049180 underperformed the KR Market which returned 13% over the past year.

Price Volatility

Is A049180's price volatile compared to industry and market?
A049180 volatility
A049180 Average Weekly Movement10.9%
Medical Equipment Industry Average Movement6.6%
Market Average Movement5.3%
10% most volatile stocks in KR Market12.0%
10% least volatile stocks in KR Market2.4%

Stable Share Price: A049180's share price has been volatile over the past 3 months.

Volatility Over Time: A049180's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
1985103In-soo Yoohttps://www.cellumed.co.kr

Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi whole, posterior tibialis, anterior tibialis, semitendinosus, gracilis, and peroneus longus tendons, and meniscus lateral and medial; cancellous bone chips and cortical cancellous dental bone powders; and femoral, tibia, radius, and ulna shafts, femur distal, tibia proximal, and cervical spacer bones.

Cellumed Co.,Ltd. Fundamentals Summary

How do CellumedLtd's earnings and revenue compare to its market cap?
A049180 fundamental statistics
Market cap₩76.69b
Earnings (TTM)-₩20.08b
Revenue (TTM)₩95.47b

0.8x

P/S Ratio

-3.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A049180 income statement (TTM)
Revenue₩95.47b
Cost of Revenue₩90.51b
Gross Profit₩4.96b
Other Expenses₩25.04b
Earnings-₩20.08b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-469.24
Gross Margin5.19%
Net Profit Margin-21.03%
Debt/Equity Ratio25.9%

How did A049180 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.